APOTHEEK VAN ACOLEYEN
ActiveSummary
APOTHEEK VAN ACOLEYEN has been active since 2008 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €485,175 and a net result of €25,227. Equity has been growing by about 9.7% per year since 2018. Its solvency ranks better than 56% of 12,775 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Overview
Official details
Source: KBO- Status
- Active since 03-01-2008 Normal situation
- Activity
- Retail sale of pharmaceutical products NACE 47730
- Joint committee
- 313 Paritair Comité voor de apotheken en tarificatiediensten · annual accounts 2025
- Establishment unit
- 2.168.124.006 1861 Meise, since 03-01-2008
- Financial year end
- 31 December
- Peppol
- Reachable since 08-01-2026
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.1%
- Gross margin
- €202,826
- ▲ 21.4%
- Turnover
- ≈ €950,000
- estimated
- Profit
- €25,227
- ▼ 51.6%
- Equity
- €485,175
- ▲ 5.5%
- Total assets
- €1.2m
- ▲ 3.5%
- Employees on 31-12-2025
- 2
- ▲ 100%
- 2025 accounts filed 25 days after the deadline
Score breakdownlowers riskLiquidity: current ratio 2.40, cash €183,427Founded in 2008Size: 1.8 FTE, total assets €1.2mFigures for financial year 2025 (filed on 25-08-2026)Show the evidence
Checked score
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 57% of them on solvency, 73% on liquidity, 38% on profitability and 53% on growth.
The bankruptcy probability was computed on 02-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 13 days after the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
Key points
- Positive: 8 profitable years in a rowprofit 2025: €25,227 8 years View
Recent changes
- · Gazette deed Company renamed from Apotheek De Boeck-Houman to APOTHEEK VAN ACOLEYENAppointments: EMVACO (director) and DIGIX (director) · Permanent representatives: VAN ACOLEYEN Emily and DIERICKX Jan · Resignations: DE BOECK Peter (director) and HOUMAN Veronique (director)
- · Gazette deed Changes of role: DE BOECK Peter (director) and HOUMAN Véronique (director)Permanent representative: DE BOECK Peter
- · Gazette deed Incorporation
Comparable companies
These companies have the same main activity as APOTHEEK VAN ACOLEYEN: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €1m and €1.2m, founded between 2004 and 2007.
| Company | Total assets | Gross margin |
|---|---|---|
| APOTHEEK VAN ACOLEYEN Meise | €1.2m | €0.2m |
| APOTHEEK BREENDONKFARMA Puurs-Sint-Amands | €1.1m | €0.2m |
| Apotheek Devos Halle | €1.0m | €0.2m |
| PHARMACIE VERLAINE Herstal | €1.1m | €0.2m |
| APOTHEEK VIAENE Deerlijk | €1.1m | €0.2m |
| PHARMACIE DU LOTHIER Genappe | €1.1m | €0.2m |
| APOTHEEK VLAEMINCK Gent | €1.2m | €0.3m |
Key facts about APOTHEEK VAN ACOLEYEN
- What is the company number of APOTHEEK VAN ACOLEYEN?
- The company number of APOTHEEK VAN ACOLEYEN is 0894.625.654. The VAT number is the same number with BE in front: BE 0894.625.654.
- Where is APOTHEEK VAN ACOLEYEN based?
- The registered office is at Gemeenteplein 1, 1861 Meise.Company details
- What does APOTHEEK VAN ACOLEYEN do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of APOTHEEK VAN ACOLEYEN?
- The legal form of APOTHEEK VAN ACOLEYEN is Private limited company (BV).
- When was APOTHEEK VAN ACOLEYEN founded?
- APOTHEEK VAN ACOLEYEN was founded on 03-01-2008.
- Is APOTHEEK VAN ACOLEYEN still active?
- Yes, APOTHEEK VAN ACOLEYEN is an active enterprise in the KBO register.
- How many employees does APOTHEEK VAN ACOLEYEN have?
- APOTHEEK VAN ACOLEYEN had an average of 1.8 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does APOTHEEK VAN ACOLEYEN fall under?
- In its 2025 annual accounts, APOTHEEK VAN ACOLEYEN states joint committee 313 (Paritair Comité voor de apotheken en tarificatiediensten).
- What is the turnover of APOTHEEK VAN ACOLEYEN?
- The turnover in financial year 2025 is ≈ €950,000. This figure is estimated from the gross margin of €202,826 and 51 comparable companies (NACE 477). It probably lies between €640,000 and €1.8m.
- Is APOTHEEK VAN ACOLEYEN profitable?
- In financial year 2025, APOTHEEK VAN ACOLEYEN made a profit of €25,227.
- Where can I find the annual accounts of APOTHEEK VAN ACOLEYEN?
- APOTHEEK VAN ACOLEYEN filed 18 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of APOTHEEK VAN ACOLEYEN due?
- APOTHEEK VAN ACOLEYEN must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.